2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Opioids, Women’s Health, Adverse Events, Biological Processes, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Immunodeficiency, Infectious Diseases, Bacterial, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4699 Hydroxyurea use is not associated with decreased albuminuria and estimated glomerular filtration rate in children and young adults with sickle cell disease: A cross-sectional analysis

Parul Rai, MD, Victoria Okhomina2, Rima Zahr, DO, MS3, Guolian Other Person Kang, PhD4, Kenneth I Ataga, MD5
1 St Jude Children's Research Hospital, Memphis, Tennessee, United States
2 St Jude Children's Research Hospital, Memphis, Tennessee, United States
3 University of Tennessee Health Sciences, Memphis, Tennessee, United States
4 St Jude Children's Research Hospital, Memphis, Tennessee, United States
5 University of Tennessee Health Sciences, Memphis, Tennessee, United States

Introduction

Kidney disease in sickle cell disease (SCD) manifests early in life and progresses with age. Glomerular hyperfiltration (HF) develops at a young age and precedes the development of persistent albuminuria (PA) and chronic kidney disease as patients age (Ataga et al., AJH 2026). Hydroxyurea (HU), the standard SCD-disease-modifying therapy, has shown some benefit in preserving organ function (Khargekar et al., Syst Rev 2024). The objective of this study was to evaluate the effect of HU on HF and PA in children and young adults with SCD.

Methods

We interrogated the database of the Sickle Cell Clinical Research and Intervention Program (SCCRIP; NCT 02098863), a lifespan SCD cohort study, and identified individuals aged 2-21 years with SCD genotype SS or Sβ0 thalassemia. Estimated glomerular filtration rate (eGFR) was estimated using the Schwartz equation in individuals <18 years and the creatinine-derived CKD-EPI-2021 equation in those ≥18 years.  HF was defined as the median of the last 3 estimated GFR >135 mL/min, and PA was defined as urinary albumin-creatinine ratio (UACR) ≥30 mg/g in at least 2 of 3 consecutive measurements or a single UACR ≥100 mg/g if preceded by a normal UACR (UACR <30mg/g).

We evaluated the cross-sectional association of HU use with UACR and eGFR (median for PA and HF, (defined above). We also conducted linear and logistic regression analyses to examine this association after adjusting for age and sex. Because the continuous forms of UACR and eGFR exhibited non-normal residuals and heteroscedasticity, a Box-Cox transformation (λ = -0.31) on UACR and a natural log transformation on eGFR were applied prior to linear regression.

Results

In our study cohort of 241 participants (49.8% female; median age 17.7 years [IQR: 12.6, 20.6]), 88% used HU as a disease-modifying therapy for at least 1 year before their last UACR measurement. The prevalence of PA in this cohort was 42% (n=101). Compared with those without PA, a higher proportion of participants with PA had HF (q=0.03), as well as higher white blood cell counts and hemolysis markers (including lower hemoglobin levels and higher absolute reticulocyte counts). No significant differences in sex, HU use, age at HU initiation, or fetal hemoglobin (HbF) level (all q>0.05) were seen cross-sectionally between the PA and non-PA groups. In the regression models, after adjusting for age and sex, HU use for at least 1 year was not significantly associated with UACR (β = 0.001, 95% CI: -0.01 to 0.01, p = 0.83) or presence of PA  (OR=1.04, 95% CI: 0.88-1.23, p=0.61). Of the 241 participants in our study cohort, eGFR was calculated for 200 participants (50.5% female; median age=18.5 [IQR: 14.6, 21.1]) and HF was observed in 61.5% (n=123). Compared with those without HF, those with HF had higher hemolysis (lower hemoglobin and higher absolute reticulocyte count), lower HbF,  and a higher proportion of participants with PA.  No significant cross-sectional differences in sex, HU use, or age at HU initiation were observed between the HF and non-HF groups. In the regression models after adjusting for age and sex, a minimum of 1 year of HU use was not associated with GFR (β = 0.001, 95% CI: -0.0002 to 0.002, p = 0.1)  or presence of HF (OR=0.94, 95% CI: 0.79 -1.13, p=0.47).

Conclusion

In our adolescent and young adult cohort, the likelihood of having PA or HF was not lowered with HU use. Consistent with previous studies, we found that the presence of PA or HF was associated with worse hemolysis, lower hemoglobin, higher WBC, and lower HbF, suggesting a contribution of hemolysis and inflammation to the pathophysiology of sickle nephropathy.  While we observed no renal benefit with HU in this cross-sectional analysis, longitudinal analyses are needed to determine whether induction of high HbF with HU delays or prevents the development of kidney disease.

Parul Rai, MD: No relevant conflicts of interest to declare.